Who's who

3 Houston innovators to know this week

This week's Houston innovators come from industries across the spectrum. Courtesy photos

This week in Houston is chock full of events from The Houston Innovation Summit, but before you get too swept away, check out these three innovators to know this week.

We have a life-long innovator whose passion has taken him from industry to industry, a construction specialist joining a growing Houston startup, and a man who let his personal struggles motivate him to find solutions.

Brad Rossacci, creative director at Accenture's Houston innovation hub

Brad Rossacci

Brad Rossacci, creative director for Accenture's Houston innovation hub, talks neuroscience, design, technology, and the upcoming Digital Fight Club on November 20 on this week's episode of the Houston Innovator's Podcast. Photo courtesy of Accenture

The guest on the Houston Innovators Podcast this week is Brad Rossacci, who's passion exudes from him in person — and podcast too. One of his recent passions? The Digital Fight Club, which is coming to Houston on November 20. The event puts two "fighters" on a stage with a referee to discuss various technology topics — cybersecurity, medicine, etc.

"I really fell in love with the approach [the event] takes," Rossacci says. "It takes this format that allows you to share ideas in a very short-form content kind of way." Read (and listen!) more.

Michael Matthews, industry principal at Data Gumbo

Michael Matthews

Data Gumbo has named the newest member of its executive team — and the newest industry it's looking to do business in. Photo courtesy of Data Gumbo

Michael Matthews was tapped to lead a brand new market that Houston blockchain startup, Data Gumbo, has announced an expansion into: Construction. The company uses blockchain to make it easier and faster to process industry contracts, payment, and more.

"The construction industry lags far behind other industries in both productivity improvement and technology adoption, resulting in billions of lost value," Matthews says in a news release. "The way companies come together to execute projects remains essentially the same despite technology's improvement and we have to make fundamental, disruptive changes to deliver more value." Read more.

Brigham Buhler, founder of Ways2Well

brigham buhler

Through his own patient journey, Brigham Buhler saw a need for Ways2Well to exist. Photo via ways2well.com

Sometimes, it's just too hard to find the answers you seek in health care. The waiting rooms, the parking, the forms — it's all a bit much only to leave empty handed. This was Brigham Buhler's experience, and finally, after months, he learned he had a hormone deficiency. Now, Buhler's company, Ways2Well, allows patients to quickly do a blood test at a lab and receive their results digitally.

"While most virtual health care providers focus on sick care — treating patients experiencing symptoms that indicate sickness — Ways2Well is focused on preventative health care," says Buhler. Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News